Previous 10 | Next 10 |
YAVNE, Israel, Oct. 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously announced registered direct and ...
MediWound ( NASDAQ: MDWD ) shares dropped 17% premarket on Thursday after the biopharmaceutical company announced ~$30.5M securities offerings. The company entered into a definitive securities purchase agreement with several investors for the sale and purchase of ~7.57M ...
YAVNE, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a defi...
The European Medicines Agency (EMA) validated for review MediWound's ( NASDAQ: MDWD ) application for expanded use of NexoBrid in children aged newborn through 18 years of age for removal of eschar (dead tissue) with deep partial-and full-thickness thermal burn wounds...
YAVNE, Israel, Sept. 20, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the European Medicines Age...
YAVNE, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced its successful and mean...
BRANFORD, Conn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced the appointment of Nachum “Homi” Shamir to its ...
The following slide deck was published by MediWound Ltd. in conjunction with their 2022 Q2 earnings call. For further details see: MediWound Ltd. 2022 Q2 - Results - Earnings Call Presentation
MediWound Ltd. (MDWD) Q2 2022 Earnings Conference Call August 9, 2022 08:30 ET Company Participants Monique Kosse - Investor Relations Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Bryan Ber...
MediWound press release ( NASDAQ: MDWD ): Q2 GAAP EPS of -$0.13 misses by $0.03 . Revenue of $4.67M (-22.8% Y/Y) misses by $0.61M . For further details see: MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M
News, Short Squeeze, Breakout and More Instantly...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...
YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share purchase agreement with several new and existing investors, including Mölnlycke...